ISR Key Statistics, Chart & Performance
The current stock price of ISR is 0.384 USD. In the past month the price increased by 37.14%. In the past year, price increased by 2.4%.
ISR Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.43 | 407.98B | ||
| AMGN | AMGEN INC | 15.07 | 177.50B | ||
| GILD | GILEAD SCIENCES INC | 15.25 | 154.97B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.49 | 116.66B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.34 | 82.03B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 782 | 52.69B | ||
| INSM | INSMED INC | N/A | 37.61B | ||
| NTRA | NATERA INC | N/A | 31.92B | ||
| BIIB | BIOGEN INC | 10.56 | 25.94B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.06 | 21.65B | ||
| INCY | INCYTE CORP | 15.47 | 19.49B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.34B |
Related stock screener links
About ISR
Company Profile
IsoRay, Inc. is a medical technology company, which engages in the development, manufacture, and sale of isotope-based medical products and devices. The company is headquartered in Richland, Washington and currently employs 66 full-time employees. The company went IPO on 2002-05-31. The firm is engaged in the advancement of treatment applications for cancers throughout the body. The company is a producer of Cesium-131 brachytherapy seeds. The firm has also developed a lead-212 generator to secure isotope supply for clinical trials and commercial operations. Its lead-212 generator utilizes the isotope lead-212 to deliver alpha radiation specifically to cancer cells via specialized targeting peptides. The firm is also engaged in the development of imaging diagnostics. The Company’s melanoma (VMT01) and neuroendocrine tumor (VMT-a-NET) programs are under Phase I/IIa imaging and therapy trials for the treatment of metastatic melanoma and neuroendocrine tumors at various academic institutions.
Company Info
ISORAY INC
350 Hills Street, Suite 106
Richland WASHINGTON 99354 US
CEO: Lori A. Woods
Employees: 66
Phone: 15093751202.0
ISORAY INC / ISR FAQ
Can you describe the business of ISORAY INC?
IsoRay, Inc. is a medical technology company, which engages in the development, manufacture, and sale of isotope-based medical products and devices. The company is headquartered in Richland, Washington and currently employs 66 full-time employees. The company went IPO on 2002-05-31. The firm is engaged in the advancement of treatment applications for cancers throughout the body. The company is a producer of Cesium-131 brachytherapy seeds. The firm has also developed a lead-212 generator to secure isotope supply for clinical trials and commercial operations. Its lead-212 generator utilizes the isotope lead-212 to deliver alpha radiation specifically to cancer cells via specialized targeting peptides. The firm is also engaged in the development of imaging diagnostics. The Company’s melanoma (VMT01) and neuroendocrine tumor (VMT-a-NET) programs are under Phase I/IIa imaging and therapy trials for the treatment of metastatic melanoma and neuroendocrine tumors at various academic institutions.
What is the current price of ISR stock?
The current stock price of ISR is 0.384 USD. The price increased by 0.03% in the last trading session.
What is the dividend status of ISORAY INC?
ISR does not pay a dividend.
What is the ChartMill rating of ISORAY INC stock?
ISR has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the Price/Earnings (PE) ratio of ISORAY INC (ISR)?
ISORAY INC (ISR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.06).
Is ISORAY INC (ISR) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on ISR.
ISR Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to ISR. When comparing the yearly performance of all stocks, ISR is one of the better performing stocks in the market, outperforming 77.63% of all stocks.
ISR Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ISR. ISR has a great financial health rating, but its profitability evaluates not so good.
ISR Financial Highlights
Over the last trailing twelve months ISR reported a non-GAAP Earnings per Share(EPS) of -0.06. The EPS decreased by -20% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
ISR Forecast & Estimates
6 analysts have analysed ISR and the average price target is 1.02 USD. This implies a price increase of 165.63% is expected in the next year compared to the current price of 0.384.
For the next year, analysts expect an EPS growth of -1% and a revenue growth 44.05% for ISR